Therapeutic options for cutaneous leishmaniasis

Mahajan, Vikram K.; Sharma, Nand Lal

doi:10.1080/09546630601159474

Cited by 14 publications

(11 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there is no water soluble, short-term and highly effective treatment that is cost effective and also free of side-effects[1,2]. In this context, it is important to note that, in both animal models and man:- (i) water soluble deoxycholate-AmB is ineffective; (ii) water soluble high dose intravenous liposomal AmB leads only to the temporary resolution of CL lesions[3-7].…”

Section: Introductionmentioning

confidence: 99%

Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid

Corware¹,

Harris²,

Teo³

et al. 2011

Biomaterials

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is a neglected tropical disease that causes prominent skin scaring. No water soluble, non-toxic, short course and low cost treatment exists. We developed a new water soluble amphotericin B-polymethacrylic acid (AmB-PMA) using established and scalable chemistries. AmB-PMA was stable for 9 months during storage. In vitro, it was effective against Leishmania spp. promastigotes and amastigote infected macrophages. It was also less toxic and more effective than deoxycholate-AmB, and similar to liposomal AmB. Its in vivo activity was determined in both early and established CL lesion models of Leishmania major infection in genetically susceptible non-healing BALB/c mice. Intradermal AmB-PMA at a total dose of 18 mg of AmB/kg body weight led to rapid parasite killing and lesion healing. No toxicity was seen. No parasite relapse occurred after 80 days follow-up. Histological studies confirmed rapid parasite clearance from macrophages followed by accelerated fibroblast mediated tissue repair, regeneration and cure of the infection. Quantitative mRNA studies of the CL lesions showed that accelerated healing was associated with increased Tumor Necrosis Factor-α and Interferon-γ, and reduced Interleukin-10. These results suggest that a cost-effective AmB-PMA could be used to pharmacologically treat and immunotherapeutically accelerate the healing of CL lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid

Corware¹,

Harris²,

Teo³

et al. 2011

Biomaterials

View full text Add to dashboard Cite

show abstract

“…12–12 Pentamidine is used to treat L. guyanensis infections 13 but not cutaneous infections caused by other Leishmania species. Several other drugs for cutaneous leishmaniasis have been proposed, including allopurinol 14 , rifampicin 15 , dapsone 16 , chloroquine 17 , and nifurtimox 18 .…”

Section: Introductionmentioning

confidence: 99%

Molecular factors governing inhibition of arylimidamides against Leishmania: Conservative computational modeling to improve chemotherapies

Collar

Zhu

Werbovetz

et al. 2011

Bioorganic & Medicinal Chemistry

View full text Add to dashboard Cite

A dataset of 55 compounds with inhibitory activity against L. donovani axenic amastigotes and L. amazonensis intracellular parasites was examined through three-dimensional quantitative structure-activity relationship modeling employing molecular descriptors from both rigid and flexible compound alignments. For training and testing purposes, the compounds were divided into two datasets of 45 and 10 compounds, respectively. Statistically significant models were constructed and validated via the internal and external predictions. For all models employing steric, electrostatic, hydrophobic, H-donor and H-acceptor molecular descriptors, the R2 values were greater than 0.90 and the SEE values were less than 0.22. The models obtained from rigid and flexible compounds were employed together to obtain a conservative method for predictions. This method minimized under predictions. Molecular descriptors from the models were then extrapolated, for the overall predictive devices and the individual compounds, and examined with regard to inhibitory activity. Information gained from the molecular descriptors is useful in the design of novel compounds. The models obtained can be employed to predict activities of the compounds designed and/or form predictions for compounds that exist and have not yet been examined with biological inhibitory assays.

show abstract

“…Evidence to support different treatments is very limited for HIV-negative CL patients (129,145) and is absent for immunocompromised HIV-coinfected patients.…”

Section: And CLmentioning

confidence: 99%

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

et al. 2008

View full text Add to dashboard Cite

SUMMARY To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of coinfection were identified, of which 90% were from Spain, Italy, France, and Portugal. However, these figures are misleading because they do not account for the large proportion of cases in many African and Asian countries that are missed due to a lack of diagnostic facilities and poor reporting systems. Most cases of coinfection in the Americas are reported in Brazil, where the incidence of leishmaniasis has spread in recent years due to overlap with major areas of HIV transmission. In some areas of Africa, the number of coinfection cases has increased dramatically due to social phenomena such as mass migration and wars. In northwest Ethiopia, up to 30% of all visceral leishmaniasis patients are also infected with HIV. In Asia, coinfections are increasingly being reported in India, which also has the highest global burden of leishmaniasis and a high rate of resistance to antimonial drugs. Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.

show abstract

Therapeutic options for cutaneous leishmaniasis

Cited by 14 publications

References 101 publications

Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid

Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid

Molecular factors governing inhibition of arylimidamides against Leishmania: Conservative computational modeling to improve chemotherapies

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

Contact Info

Product

Resources

About